Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during care pulmonary thromboembolism (2012)
- Authors:
- USP affiliated authors: GERLACH, RAQUEL FERNANDA - FORP ; SANTOS, JOSE EDUARDO TANUS DOS - FMRP
- Unidades: FORP; FMRP
- DOI: 10.1007/s00210-012-0748-9
- Subjects: ANTIOXIDANTES; TROMBOEMBOLISMO; METALOPROTEINASES; TROPONINA I
- Language: Inglês
- Imprenta:
- Publisher place: Heidelberg
- Date published: 2012
- Source:
- Título: Naunyn-Schmiedeberg's Archives Pharmacology
- ISSN: 0028-1298
- Volume/Número/Paginação/Ano: v. 385, n. 7, p. 685-696, 2012
- Este artigo possui versão em acesso aberto
- URL de acesso aberto
- Versão do Documento: Versão submetida (Pré-print)
-
Status: Artigo possui versão em acesso aberto em repositório (Green Open Access) -
ABNT
SOUSA-SANTOS, Ozelia et al. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during care pulmonary thromboembolism. Naunyn-Schmiedeberg's Archives Pharmacology, v. 385, n. 7, p. 685-696, 2012Tradução . . Disponível em: https://doi.org/10.1007/s00210-012-0748-9. Acesso em: 16 mar. 2026. -
APA
Sousa-Santos, O., Neves, E. M. N., Ferraz, K. C., Ceron, C. S., Rizzi, E., Gerlach, R. F., & Tanus-Santos, J. E. (2012). Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during care pulmonary thromboembolism. Naunyn-Schmiedeberg's Archives Pharmacology, 385( 7), 685-696. doi:10.1007/s00210-012-0748-9 -
NLM
Sousa-Santos O, Neves EMN, Ferraz KC, Ceron CS, Rizzi E, Gerlach RF, Tanus-Santos JE. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during care pulmonary thromboembolism [Internet]. Naunyn-Schmiedeberg's Archives Pharmacology. 2012 ; 385( 7): 685-696.[citado 2026 mar. 16 ] Available from: https://doi.org/10.1007/s00210-012-0748-9 -
Vancouver
Sousa-Santos O, Neves EMN, Ferraz KC, Ceron CS, Rizzi E, Gerlach RF, Tanus-Santos JE. Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during care pulmonary thromboembolism [Internet]. Naunyn-Schmiedeberg's Archives Pharmacology. 2012 ; 385( 7): 685-696.[citado 2026 mar. 16 ] Available from: https://doi.org/10.1007/s00210-012-0748-9 - Recombinant human matrix metalloproteinase-2 impairs cardiovascular 'beta'-adrenergic responses
- Circulating cell-free DNA levels in plasma increase with severity in experimental acute pulmonary thromboembolism
- The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension
- Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin
- Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome
- Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension
- Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension
- Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress
- Chronic treatment with nebivolol attenuates the vascular changes in the 2-kidney, 1-clip model of renovascular hypertension
- Circulating matrix metalloproteinases and their inhibitors in hypertension
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
